These are top 10 stocks traded on the Robinhood UK platform in July
On Monday, TD Cowen analyst Charles Rhyee adjusted the firm’s view on ICON plc (NASDAQ:ICLR), downgrading the stock from Buy to Hold and significantly reducing the price target from $254.00 to $157.00. The stock, which has declined over 51% in the past six months and is trading near its 52-week low of $138.51, faces renewed pressure as optimism for a demand rebound in the second half of 2025 waned based on recent findings. According to InvestingPro data, six analysts have recently revised their earnings expectations downward for the upcoming period.
Rhyee initially anticipated a resurgence in demand for ICON’s services as the biopharmaceutical industry completed a cycle of reprioritization, potentially leading to accelerated growth in 2026. However, subsequent checks and analysis have led to a more cautious outlook. According to Rhyee, the ongoing shift towards Functional Service Provider (FSP) models is expected to impact ICON particularly hard in both 2025 and 2026. Despite these challenges, InvestingPro analysis shows ICON maintains strong financial health with an overall score of 3.23/5, supported by $8.28 billion in revenue over the last twelve months.
The revised price target of $157.00 reflects a new perspective on ICON’s future performance. Rhyee elaborated on the reasons behind the downgrade, citing the shift to FSP as a significant factor likely to affect the company’s growth trajectory over the next two years.
ICON, a global provider of outsourced development services to the pharmaceutical, biotechnology, and medical device industries, is now viewed with less certainty regarding its near-term growth prospects. The analyst’s comments underscore the challenges ICON may face as industry dynamics evolve.
The downgrade and price target adjustment for ICON by TD Cowen represent a notable shift in expectations for the company’s performance. Investors are now presented with a more conservative outlook as the market adapts to changing trends within the biopharma sector.
In other recent news, ICON plc has been the focus of multiple analyst revisions following its latest developments. Truist Securities has lowered its price target for ICON to $208, maintaining a Buy rating, while Barclays (LON:BARC) has downgraded the stock from Overweight to Equalweight, setting a new price target of $165. Goldman Sachs also revised its outlook, downgrading ICON from Buy to Neutral and reducing the price target to $200, citing a weaker demand environment. Evercore ISI, however, maintained an Outperform rating with a steady price target of $225, despite a delay in a major COVID vaccine study.
The delay in the vaccine study is expected to impact ICON’s revenue for the first half of 2025, with an estimated financial impact of $40-80 million. Truist Securities and Evercore ISI have both noted that the delay will not alter ICON’s full-year 2025 guidance. Barclays highlighted challenges from ICON’s customer concentration and BARDA contract impacts, while Goldman Sachs expressed confidence in ICON’s long-term prospects despite near-term uncertainties. Truist Securities has adjusted its revenue estimates for 2025 and 2026 to $8,076 million and $8,456 million, respectively, reflecting the updated expectations.
These analyst assessments underscore the mixed outlook for ICON, as the company navigates through current challenges while maintaining a focus on its long-term growth potential.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.